This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Chongqing Pharmaceutical Research Institute Co., Ltd, Yaopharma Co., Ltd.. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Innovations of Shuai He in Pharmaceutical Research
Introduction
Shuai He is a notable inventor based in Chongqing, China. He has made significant contributions to the field of pharmaceutical research, particularly in the development of crystalline forms of fluvatinib. His work has implications for the manufacturing processes of fluvatinib methanesulfonate formulations.
Latest Patents
Shuai He holds 1 patent for his invention titled "Crystalline form of fluvatinib or fluvatinib methanesulfonate and preparation method therefor." This patent discloses a crystalline form of fluvatinib, which exhibits characteristic diffraction peaks. The invention also details multiple crystalline forms of fluvatinib methanesulfonate, including seven distinct forms, with crystalline form III having its own unique diffraction peaks. These crystalline forms are designed to enhance the manufacturing processes for fluvatinib methanesulfonate formulations.
Career Highlights
Throughout his career, Shuai He has worked with prominent organizations in the pharmaceutical industry. He has been associated with the Chongqing Pharmaceutical Research Institute Co., Ltd and Yaopharma Co., Ltd. His experience in these institutions has allowed him to refine his expertise in drug formulation and development.
Collaborations
Shuai He has collaborated with several professionals in his field, including Yang Zhang and Qiang Liu. These collaborations have contributed to the advancement of his research and the successful development of his patented inventions.
Conclusion
Shuai He is a distinguished inventor whose work in the pharmaceutical sector has led to innovative advancements in drug formulation. His contributions, particularly in the area of fluvatinib, demonstrate his commitment to enhancing pharmaceutical manufacturing processes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile